Chicago, IL 的 三陰性乳癌 臨床試驗
16 項針對 三陰性乳癌 的研究正在 Chicago（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- University of Chicago Hospital, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
招募中1/2 期
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
招募中3 期
- University of Illinois Cancer Center ( Site 0044), Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
招募中1 期
- Northwestern University Feinberg School of Medicine, Chicago
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- Northwestern Medicine, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
招募中1/2 期
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Local Institution - 0280, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Northwestern University, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
招募中1 期
- The University of Chicago Medical Center (UCMC), Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
Study of XB010 in Subjects With Solid Tumors
招募中1 期
- University of Chicago Medical Center, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
招募中1/2 期
- Northwestern Memorial Hospital, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
招募中2 期
- University of Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
招募中2 期
- University of Chicago Medical Center, Chicago
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
招募中1 期
- UChicago Medicine Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- University of Chicago, Chicago
其他城市的 三陰性乳癌 試驗
- Houston, TX42 項研究
- New York City, NY31 項研究
- Nashville, TN28 項研究
- Los Angeles, CA27 項研究
- Boston, MA26 項研究
- San Antonio, TX23 項研究
- St. Louis, MO21 項研究
- Arlington, VA20 項研究
- Atlanta, GA20 項研究
- Dallas, TX18 項研究
- Columbus, OH16 項研究
- Grand Rapids, MI15 項研究
Chicago 的其他研究
- 非小細胞肺癌61 項研究
- 乳癌59 項研究
- 癌症（所有類型）51 項研究
- 轉移性癌症45 項研究
- 前列腺癌45 項研究
- 肺癌41 項研究
- 肥胖症41 項研究
- 卵巢癌36 項研究
- 大腸直腸癌34 項研究
- 中風34 項研究
- 心臟衰竭31 項研究
- 過重29 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。